top of page
Shield Overview2.png
Guardant Shield

血液基因篩檢

可有效篩檢早期大腸癌(CRC)

Common CRC biomarkers
Active Senior Couple_edited.jpg

用於早期癌症徵兆篩檢的血液檢測

如今,三分之一的成年人沒有完成建議的結直腸癌篩檢。而血液檢測可以改善這一情況,因為它克服了現有方法的一些障礙,包括結腸鏡檢查和基於大便的測試。雖然這些方法是有效的,但可能令人不舒服、耗時且難以完成。

READ MORE

我們與Guardant Health合作
​照顧您不同的需要

Guardant Health product lines

*The U.S. Food and Drug Administration (FDA) grants oversight of Lab Developed Tests (LDTs) to the Centers for Medicare & Medicaid Services (CMS). LDTs are regulated by CMS under the Clinical Laboratory Improvement Amendment (CLIA), which subjects LDTs to strict personnel, quality control, and proficiency testing standards.8

1. Data on file. Guardant Health, Inc. 2. Evaluation of the ctDNA LUNAR test in an average patient screening episode (ECLIPSE). ClinicalTrials.gov identifier: NCT04136002. https://clinicaltrials.gov/ct2/show/NCT04136002?term=NCT04136002&draw=2&rank=1
3. American Society of Clinical Oncology. Colorectal cancer: statistics. https://www.cancer.net/cancer-types/colorectal-cancer/statistics 4. Guardant Health initiates ORACLE study to evaluate performance of Guardant Reveal™ Blood Test to predict recurrence across
early-stage cancers. https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant-Health-Initiates-ORACLE-Study-to-Evaluate-Performance-of-Guardant-Reveal-Blood-Test-to-Predict-Recurrence-Across-Early-Stage-Cancers/default.aspx
5. Guardant Health expands Guardant360® portfolio with new tests for treatment response monitoring and complete genomic profiling. https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant-Health-Expands-Guardant360-Portfolio-
With-New-Tests-for-Treatment-Response-Monitoring-and-Complete-Genomic-Profiling/default.aspx 6. Guardant Health receives expanded Medicare coverage for Guardant360 across the vast majority of solid tumor cancers. https://investors.guardanthealth.com/
press-releases/press-releases/2019/Guardant-Health-Receives-Expanded-Medicare-Coverage-for-Guardant360-Across-the-Vast-Majority-of-Solid-Tumor-Cancers/default.aspx 7. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test 8. D’Angelo, R., Weiss, R., Wolfe, D., Chinnam, R., Murat, A., Gluesing, J., & Somers, T. (2018). Being Prepared for Regulatory Requirements for Laboratory Developed Tests. American Journal of Clinical Pathology, 149(6), 484–498. https://doi.org/10.1093/AJCP/AQY014

bottom of page